Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

被引：10

作者：

Chisholm, Julia ^{[1
,2
]}

Mandeville, Henry ^{[1
,2
]}

Adams, Madeleine ^{[3
]}

Minard-Collin, Veronique ^{[4
]}

Rogers, Timothy ^{[5
]}

Kelsey, Anna ^{[6
]}

Shipley, Janet ^{[7
]}

van Rijn, Rick R. ^{[8
]}

de Vries, Isabelle ^{[9
]}

van Ewijk, Roelof ^{[9
]}

de Keizer, Bart ^{[9
]}

Gatz, Susanne A. ^{[10
,11
]}

Casanova, Michela ^{[12
]}

Hjalgrim, Lisa Lyngsie ^{[13
]}

Firth, Charlotte ^{[11
]}

Wheatley, Keith ^{[11
]}

Kearns, Pamela ^{[11
]}

Liu, Wenyu ^{[11
]}

Kirkham, Amanda ^{[11
]}

Rees, Helen ^{[14
]}

Bisogno, Gianni ^{[15
]}

Wasti, Ajla ^{[7
]}

Wakeling, Sara ^{[16
]}

Heenen, Delphine ^{[17
]}

Tweddle, Deborah A. ^{[18
]}

Merks, Johannes H. M. ^{[9
]}

Jenney, Meriel ^{[3
]}

机构：

[1] Royal Marsden Hosp, Children & Young Peoples Unit, Sutton SM2 5PT, England

[2] Inst Canc Res, Sutton SM2 5PT, England

[3] Childrens Hosp Wales, Dept Paediat Surg, Cardiff CF14 4XW, Wales

[4] Gustave Roussy, Dept Paediat Oncol, F-75015 Paris, France

[5] Univ Hosp Bristol & Weston NHS Fdn Trust, Dept Paediat Surg, Bristol BS1 3NU, England

[6] Manchester Univ NHS Fdn Trust, Royal Manchester Childrens Hosp, Dept Paediat Histopathol, Manchester M13 9WL, England

[7] Inst Canc Res, London SW7 3RP, England

[8] Univ Amsterdam, Dept Radiol & Nucl Med, Amsterdam UMC, NL-1081 HV Amsterdam, Netherlands

[9] Princess Maxima Ctr Pediat Oncol, NL-3584 CS Utrecht, Netherlands

[10] Birmingham Womens & Childrens NHS Fdn Trust, Birmingham B15 2TG, England

[11] Univ Birmingham, Inst Canc & Genom Sci, Canc Res UK Clin Trials Unit, Birmingham B15 2TT, England

[12] Fdn IRCCS Ist Nazl Tumori, I-20133 Milan, Italy

[13] Univ Hosp Copenhagen, DK-2200 Copenhagen, Denmark

[14] Univ Hosp Bristol & Weston NHS Fdn Trust, Dept Paediat Oncol, Bristol BS1 3NU, England

[15] Univ Padua, Dept Women & Childrens Hlth, I-35122 Padua, Italy

[16] Alices Arc Charity, London EC1V 1AW, England

[17] KickCancer Fdn, B-1000 Brussels, Belgium

[18] Newcastle Univ, Translat & Clin Res Inst, Vivo Biobank, Ctr Canc, Newcastle Upon Tyne NE1 7RU, England

来源：

CANCERS | 2024年 / 16卷 / 05期

关键词：

rhabdomyosarcoma; clinical trial; chemotherapy; radiotherapy; randomisation; novel agents; FaR-RMS; EpSSG; PET RESPONSE CRITERIA; QUALITY-OF-LIFE; PHASE-II; RADIATION-THERAPY; STUDY-IV; NONMETASTATIC RHABDOMYOSARCOMA; RISK RHABDOMYOSARCOMA; INTERNATIONAL SOCIETY; PROGNOSTIC-FACTORS; YOUNG-ADULTS;

D O I：

10.3390/cancers16050998

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study Group (EpSSG), incorporates multiple different research questions within a multistage design with a focus on (i) novel regimens for poor prognostic subgroups, (ii) optimal duration of maintenance chemotherapy, and (iii) optimal use of radiotherapy for local control and widespread metastatic disease. Additional sub-studies focusing on biological risk stratification, use of imaging modalities, including [F-18]FDG PET-CT and diffusion-weighted MRI imaging (DWI) as prognostic markers, and impact of therapy on quality of life are described. This paper forms part of a Special Issue on rhabdomyosarcoma and outlines the study background, rationale for randomisations and sub-studies, design, and plans for utilisation and dissemination of results.

引用

页数：24

共 50 条

[1] Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)( vol 16, 998, 2024)
Chisholm, Julia
Mandeville, Henry
Adams, Madeleine
Minard-Collin, Veronique
Rogers, Timothy
Kelsey, Anna
Shipley, Janet
van Rijn, Rick R.
de Vries, Isabelle
van Ewijk, Roelof
de Keizer, Bart
Gatz, Susanne A.
Casanova, Michela
Hjalgrim, Lisa Lyngsie
Firth, Charlotte
Wheatley, Keith
Kearns, Pamela
Liu, Wenyu
Kirkham, Amanda
Rees, Helen
Bisogno, Gianni
Wasti, Ajla
Wakeling, Sara
Heenen, Delphine
Tweddle, Deborah A.
Merks, Johannes H. M.
Jenney, Meriel
CANCERS, 2024, 16 (19)
[2] Revisiting Risk Stratification in Patients with Localized Rhabdomyosarcoma (RMS): A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EPSSG)
Bisogno, G.
Jenney, M.
Gallego, S.
Bergeron, C.
Merks, J. H.
Julia, C.
Ferrari, A.
Angelica, Z.
Martelli, H.
Kelsey, A.
Glosli, H.
Colin, V. Minard
Ben-Arush, M.
Zanetti, I.
De Salvo, G. L.
PEDIATRIC BLOOD & CANCER, 2017, 64 : S49 - S50
[3] Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).
Bisogno, Gianni
De Salvo, Gian Luca
Bergeron, Christophe
Jenney, Meriel
Merks, Johannes H. M.
Minard-Colin, Veronique
Orbach, Daniel
Glosli, Heidi
Chisholm, Julia
Casanova, Michela
Melcon, Soledad Gallego
Ferrari, Andrea
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
[4] Congenital rhabdomyosarcoma: A report from the European paediatric Soft tissue sarcoma Study Group
Bisogno, Gianni
Minard-Colin, Veronique
Ben Arush, Myriam
Daragjati, Julia
Coppadoro, Beatrice
Gallego, Soledad
Alaggio, Rita
Smeulders, Naima
Mudry, Peter
Zin, Angelica
Merks, Johannes H. M.
Slater, Olga
PEDIATRIC BLOOD & CANCER, 2021,
[5] Rhabdomyosarcoma in Infants and Children Under 36 Months of Age Treated on the European Paediatric Soft Tissue Sarcoma Group (EPSSG) RMS2005 Study
Slater, O.
Gains, J.
Kelsey, A.
De Corti, F.
Smeulders, N.
Zanetti, I.
Coppadoro, B.
Jorgensen, M.
Gallego, S.
Orbach, D.
Minard-Colin, V.
Glosli, H.
Cesen, M.
Gaze, M.
Ferrari, A.
Jenney, M.
Bisogno, G.
Merks, J.
PEDIATRIC BLOOD & CANCER, 2021, 68 : S256 - S257
[6] Assessing the Risk Profile of Rhabdomyosarcoma (RMS) Patients in a New Classification System for the Next European Paediatric Soft Tissue Sarcoma Study Group (EPSSG) Protocol
Bisogno, G.
Jenney, M.
Merks, J. H. M.
Minard-Colin, V.
Daragjati, J.
Zanetti, I.
Gallego, S.
Shipley, J.
Ferrari, A.
Chisholm, J.
Kelsey, A.
Mandeville, H.
Rogers, T.
Orbach, D.
Bergeron, C.
De Salvo, G. L.
PEDIATRIC BLOOD & CANCER, 2019, 66 : S63 - S64
[7] Paratesticular rhabdomyosarcoma-Impact of locoregional approach on patient outcome: A report from the European paediatric Soft tissue sarcoma Study Group (EpSSG)
Rogers, Timothy N.
De Corti, Federica
Guillen Burrieza, Gabriela
Guerin, Florent
van Scheltinga, Sheila Terwisscha
Snneulders, Naima
Craigie, Ross
Jenney, Meriel
Kelsey, Anna
Zanetti, Hada
Coppadoro, Beatrice
De Salvo, Gian Luca
Bisogno, Gianni
Martelli, Helene
PEDIATRIC BLOOD & CANCER, 2020, 67 (09)
[8] Outcome of localized liver-bile duct rhabdomyosarcoma according to local therapy: A report from the European Paediatric Soft-Tissue Sarcoma Study Group (EpSSG)-RMS 2005 study
Guerin, Florent
Rogers, Timothy
Minard-Colin, Veronique
Gaze, Mark N.
Terwisscha, Sheila
Van Noesel, Max
De Corti, Federica
Burrieza, Gabriela Guillen
De Salvo, Gian Luca
Kelsey, Anna
Orbach, Daniel
Ferrari, Andrea
Bergeron, Christophe
Bisogno, Gianni
Martelli, Helene
PEDIATRIC BLOOD & CANCER, 2019, 66 (07)
[9] Rhabdomyosarcoma with unknown primary tumor site: A report from European pediatric Soft tissue sarcoma Study Group (EpSSG)
Affinita, Maria Carmen
Merks, Johannes H. M.
Chisholm, Julia C.
Haouy, Stephanie
Rome, Angelique
Rabusin, Marco
Brennan, Bernadette
Bisogno, Gianni
PEDIATRIC BLOOD & CANCER, 2022, 69 (12)
[10] FaR-RMS: Frontline and Relapsed Rhabdomyosarcoma. A Study for Children and Adults with randomized Questions about Radiotherapy
Sparber-Sauer, M.
Timmermann, B.
Harrabi, S.
Lin, Y. -L.
Muenter, M.
Ebinger, M.
STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (SUPPL 1) : S182 - S183

← 1 2 3 4 5 →